BIRC5 and breast carcinoma: Anthracycline-based chemotherapy showed pCR benefit of 26.1% (n=1) vs 4.3% (n=1) in Bcl-2- and Bcl2+ breast cancer patients, 35.0% (n=1) vs 8.6% (n=1) in high and low Smac, and 28.3% (n=1) vs 11.5% (n=1) in low and high Survivin.